Patterns of pharmacotherapy for bipolar disorder: A GBC survey
Balwinder Singh
(1)
,
Anastasia Yocum
(2)
,
Rebecca Strawbridge
(3)
,
Katherine Burdick
(4, 5)
,
Caitlin Millett
(4, 5)
,
Amy Peters
(4, 6)
,
Sarah Sperry
(2)
,
Giovanna Fico
(7, 8, 9)
,
Eduard Vieta
(7, 8, 9)
,
Norma Verdolini
(7, 8, 9, 10)
,
Ophelia Godin
(11, 12, 13)
,
Marion Leboyer
(11, 12, 13)
,
Bruno Etain
(14, 15, 16)
,
Ivy Tso
(2, 17)
,
Brandon Coombes
(1)
,
Melvin Mcinnis
(2)
,
Andrew Nierenberg
(4, 6)
,
Allan Young
(3)
,
Melanie Ashton
(18)
,
Michael Berk
(18, 19)
,
Lana Williams
(18)
,
Kamyar Keramatian
(20)
,
Lakshmi Yatham
(20)
,
Bronwyn Overs
(21)
,
Janice Fullerton
(21, 22)
,
Gloria Roberts
(22)
,
Philip Mitchell
(22)
,
Ole Andreassen
(23, 24)
,
Ana Andreazza
(25)
,
Peter Zandi
(26)
,
Daniel Pham
(27)
,
Joanna Biernacka
(1, 16, 14)
,
Mark Frye
(1)
1
Mayo Clinic [Rochester]
2 University of Michigan [Ann Arbor]
3 King‘s College London
4 HMS - Harvard Medical School [Boston]
5 Brigham and Women’s Hospital [Boston, MA]
6 Massachusetts General Hospital [Boston]
7 University of Barcelona
8 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
9 CIBER-SAM - Centro de Investigación Biomédica en Red Salud Mental [Madrid]
10 Azienda USL Umbria 1 - USL Umbria 1 [Perugia, Italy]
11 U955 Inserm - UPEC - IMRB - "Neuropsychiatrie translationnelle" [Créteil]
12 Fondation FondaMental [Créteil]
13 Hôpital Henri Mondor
14 OPTeN (UMR_S 1144 / U1144) - Optimisation thérapeutique en Neuropsychopharmacologie
15 GHU AP-HP Nord - Université Paris Cité
16 Hôpital Lariboisière-Fernand-Widal [APHP]
17 OSU - Ohio State University [Columbus]
18 Deakin University
19 University of Melbourne
20 UBC - University of British Columbia
21 NeuRA - Neuroscience Research Australia
22 UNSW - University of New South Wales [Sydney]
23 UiO - University of Oslo
24 Oslo University Hospital [Oslo]
25 University of Toronto
26 Johns Hopkins University School of Medicine [Baltimore]
27 Milken Institute School of Public Health
2 University of Michigan [Ann Arbor]
3 King‘s College London
4 HMS - Harvard Medical School [Boston]
5 Brigham and Women’s Hospital [Boston, MA]
6 Massachusetts General Hospital [Boston]
7 University of Barcelona
8 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
9 CIBER-SAM - Centro de Investigación Biomédica en Red Salud Mental [Madrid]
10 Azienda USL Umbria 1 - USL Umbria 1 [Perugia, Italy]
11 U955 Inserm - UPEC - IMRB - "Neuropsychiatrie translationnelle" [Créteil]
12 Fondation FondaMental [Créteil]
13 Hôpital Henri Mondor
14 OPTeN (UMR_S 1144 / U1144) - Optimisation thérapeutique en Neuropsychopharmacologie
15 GHU AP-HP Nord - Université Paris Cité
16 Hôpital Lariboisière-Fernand-Widal [APHP]
17 OSU - Ohio State University [Columbus]
18 Deakin University
19 University of Melbourne
20 UBC - University of British Columbia
21 NeuRA - Neuroscience Research Australia
22 UNSW - University of New South Wales [Sydney]
23 UiO - University of Oslo
24 Oslo University Hospital [Oslo]
25 University of Toronto
26 Johns Hopkins University School of Medicine [Baltimore]
27 Milken Institute School of Public Health
Balwinder Singh
- Fonction : Auteur
- PersonId : 1281079
- ORCID : 0000-0001-7062-8192
Anastasia Yocum
- Fonction : Auteur
- PersonId : 1281080
- ORCID : 0000-0002-1592-0825
Rebecca Strawbridge
- Fonction : Auteur
- PersonId : 824236
- ORCID : 0000-0002-2984-1124
Katherine Burdick
- Fonction : Auteur
- PersonId : 824233
- ORCID : 0000-0003-4417-4988
Amy Peters
- Fonction : Auteur
Sarah Sperry
- Fonction : Auteur
- PersonId : 1281081
- ORCID : 0000-0002-1111-7357
Giovanna Fico
- Fonction : Auteur
- PersonId : 1281082
- ORCID : 0000-0003-1785-7126
Eduard Vieta
- Fonction : Auteur
- PersonId : 1187713
- ORCID : 0000-0002-0548-0053
Ophelia Godin
- Fonction : Auteur
- PersonId : 1093297
- IdHAL : ophelia-godin
- ORCID : 0000-0001-5004-5475
Bruno Etain
- Fonction : Auteur
- PersonId : 757741
- IdHAL : bruno-etain
- ORCID : 0000-0002-5377-1488
- IdRef : 074181106
Ivy Tso
- Fonction : Auteur
- PersonId : 1281083
- ORCID : 0000-0002-0984-1186
Brandon Coombes
- Fonction : Auteur
- PersonId : 1281084
- ORCID : 0000-0003-4322-5923
Kamyar Keramatian
- Fonction : Auteur
- PersonId : 1281085
- ORCID : 0000-0003-4958-6025
Janice Fullerton
- Fonction : Auteur
- PersonId : 792529
- ORCID : 0000-0003-4014-4490
Ana Andreazza
- Fonction : Auteur
- PersonId : 1281086
- ORCID : 0000-0002-4323-7273
Peter Zandi
- Fonction : Auteur
- PersonId : 1248698
- ORCID : 0000-0001-8423-2623
Joanna Biernacka
- Fonction : Auteur
- PersonId : 805585
- ORCID : 0000-0001-9350-4440
Résumé
Abstract Objectives To understand treatment practices for bipolar disorders (BD), this study leveraged the Global Bipolar Cohort collaborative network to investigate pharmacotherapeutic treatment patterns in multiple cohorts of well‐characterized individuals with BD in North America, Europe, and Australia. Methods Data on pharmacotherapy, demographics, diagnostic subtypes, and comorbidities were provided from each participating cohort. Individual site and regional pooled proportional meta‐analyses with generalized linear mixed methods were conducted to identify prescription patterns. Results This study included 10,351 individuals from North America ( n = 3985), Europe ( n = 3822), and Australia ( n = 2544). Overall, participants were predominantly female (60%) with BD‐I (60%; vs. BD‐II = 33%). Cross‐sectionally, mood‐stabilizing anticonvulsants (44%), second‐generation antipsychotics (42%), and antidepressants (38%) were the most prescribed medications. Lithium was prescribed in 29% of patients, primarily in the Australian (31%) and European (36%) cohorts. First‐generation antipsychotics were prescribed in 24% of the European versus 1% in the North American cohort. Antidepressant prescription rates were higher in BD‐II (47%) compared to BD‐I (35%). Major limitations were significant differences among cohorts based on inclusion/exclusion criteria, data source, and time/year of enrollment into cohort. Conclusions Mood‐stabilizing anticonvulsants, second‐generation antipsychotics, and antidepressants were the most prescribed medications suggesting prescription patterns that are not necessarily guideline concordant. Significant differences exist in the prescription practices across different geographic regions, especially the underutilization of lithium in the North American cohorts and the higher utilization of first‐generation antipsychotics in the European cohorts. There is a need to conduct future longitudinal studies to further explore these differences and their impact on outcomes, and to inform and implement evidence‐based guidelines to help improve treatment practices in BD.